Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...
The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...
NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
The Alzheimer's Drug Discovery Foundation (ADDF) marked its Inaugural ADDF Scientific Summit in a momentous celebration of Alzheimer's science which brought together the ...
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
MicroStrategy’s Andrew Kang talks about bitcoin holdings, Krispy Kreme’s Jeremiah Ashukian discusses business model changes and Lemonade’s Tim Bixby shares growth stats.
We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...
It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has ...
Lone Pine Capital, established in 1997 by Stephen Mandel, is a leading hedge fund and investment advisory firm based in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback